AR072807A1 - Formas solidas del compuestos (2r,3r,4r,5s,6r)-2-(4-cloro-3-etoxibencil)fenil)6-(metiltio)tetahidro-2h-piran-3,4,5-triol y metodos para su uso como inhibidor del cotransportador 2 de sodio-glucosa (sglt2) - Google Patents
Formas solidas del compuestos (2r,3r,4r,5s,6r)-2-(4-cloro-3-etoxibencil)fenil)6-(metiltio)tetahidro-2h-piran-3,4,5-triol y metodos para su uso como inhibidor del cotransportador 2 de sodio-glucosa (sglt2)Info
- Publication number
- AR072807A1 AR072807A1 ARP090102685A ARP090102685A AR072807A1 AR 072807 A1 AR072807 A1 AR 072807A1 AR P090102685 A ARP090102685 A AR P090102685A AR P090102685 A ARP090102685 A AR P090102685A AR 072807 A1 AR072807 A1 AR 072807A1
- Authority
- AR
- Argentina
- Prior art keywords
- triol
- chloro
- phenyl
- etoxibencil
- tetahydro
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 102100020888 Sodium/glucose cotransporter 2 Human genes 0.000 title 2
- 101710103228 Sodium/glucose cotransporter 2 Proteins 0.000 title 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- QKDRXGFQVGOQKS-CRSSMBPESA-N (2s,3r,4r,5s,6r)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylsulfanyloxane-3,4,5-triol Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](SC)O2)O)=CC=C1Cl QKDRXGFQVGOQKS-CRSSMBPESA-N 0.000 abstract 2
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/08—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium or tellurium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8142308P | 2008-07-17 | 2008-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072807A1 true AR072807A1 (es) | 2010-09-22 |
Family
ID=41137707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102685A AR072807A1 (es) | 2008-07-17 | 2009-07-15 | Formas solidas del compuestos (2r,3r,4r,5s,6r)-2-(4-cloro-3-etoxibencil)fenil)6-(metiltio)tetahidro-2h-piran-3,4,5-triol y metodos para su uso como inhibidor del cotransportador 2 de sodio-glucosa (sglt2) |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US8217156B2 (enExample) |
| EP (1) | EP2332947B1 (enExample) |
| JP (2) | JP2011528366A (enExample) |
| KR (2) | KR20170010069A (enExample) |
| CN (2) | CN107629097A (enExample) |
| AR (1) | AR072807A1 (enExample) |
| AU (1) | AU2009270973B2 (enExample) |
| BR (1) | BRPI0916191A2 (enExample) |
| CA (1) | CA2730931A1 (enExample) |
| CL (1) | CL2009001595A1 (enExample) |
| CO (1) | CO6351797A2 (enExample) |
| DK (1) | DK2332947T3 (enExample) |
| ES (1) | ES2656357T3 (enExample) |
| HK (1) | HK1243713A1 (enExample) |
| HU (1) | HUE035400T2 (enExample) |
| IL (1) | IL210269A (enExample) |
| MX (1) | MX2011000503A (enExample) |
| NO (1) | NO2332947T3 (enExample) |
| NZ (1) | NZ590184A (enExample) |
| PE (1) | PE20100260A1 (enExample) |
| PL (1) | PL2332947T3 (enExample) |
| PT (1) | PT2332947T (enExample) |
| RU (1) | RU2505543C2 (enExample) |
| SG (1) | SG185317A1 (enExample) |
| TW (1) | TWI472521B (enExample) |
| UA (1) | UA106048C2 (enExample) |
| UY (1) | UY31992A (enExample) |
| WO (1) | WO2010009197A1 (enExample) |
| ZA (1) | ZA201100175B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI499414B (zh) * | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法 |
| JP5653213B2 (ja) | 2007-07-26 | 2015-01-14 | レクシコン ファーマシューティカルズ インコーポレイテッド | ナトリウム・グルコース共輸送体２阻害剤の調製に有用な方法及び化合物 |
| US9061060B2 (en) | 2008-07-15 | 2015-06-23 | Theracos Inc. | Deuterated benzylbenzene derivatives and methods of use |
| TWI472521B (zh) | 2008-07-17 | 2015-02-11 | Lexicon Pharmaceuticals Inc | （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法 |
| TWI562775B (en) * | 2010-03-02 | 2016-12-21 | Lexicon Pharmaceuticals Inc | Methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| CN102453026A (zh) | 2010-10-27 | 2012-05-16 | 上海艾力斯医药科技有限公司 | C-芳基葡糖苷衍生物、制备方法及其应用 |
| TWI631963B (zh) * | 2011-01-05 | 2018-08-11 | 雷西肯製藥股份有限公司 | 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| RU2015123738A (ru) * | 2012-11-20 | 2017-01-10 | Лексикон Фармасьютикалз, Инк. | Ингибиторы котранспортера натрий-глюкозы 1 |
| CA2922044A1 (en) | 2013-10-18 | 2015-05-14 | Medivation Technologies, Inc. | Pyrazolo-, imidazolo- and pyrrolo-pyridine or -pyrimidine derivatives as inhibitors o brutons kinase (btk) |
| WO2015058084A1 (en) | 2013-10-18 | 2015-04-23 | Medivation Technologies, Inc. | Heterocyclic compounds and methods of use |
| EP3498723A1 (en) | 2015-07-30 | 2019-06-19 | Microbial Chemistry Research Foundation | New effective aminoglycoside antibiotic for multidrug-resistant bacteria |
| CN109195980B (zh) * | 2016-05-25 | 2022-05-17 | 苏州科睿思制药有限公司 | 一种钠-葡萄糖协同转运蛋白抑制剂药物的新晶型及其制备方法和用途 |
| WO2018067805A1 (en) | 2016-10-06 | 2018-04-12 | Teva Pharmaceutical Industries Ltd. | Solid state forms of sotagliflozin |
| EA201990951A1 (ru) | 2016-10-19 | 2019-11-29 | Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение | |
| EP3781166A1 (en) | 2018-04-17 | 2021-02-24 | Boehringer Ingelheim International GmbH | Pharmaceutical composition, methods for treating and uses thereof |
| CN110818722B (zh) * | 2018-08-14 | 2022-12-02 | 苏州鹏旭医药科技有限公司 | 三种化合物及其制备方法和在合成索格列净中的用途 |
| BR112020024296A2 (pt) | 2018-08-27 | 2021-03-09 | Regeneron Pharmaceuticals, Inc. | Métodos para produção de um intermediário de purificação de proteína concentrado, para monitoramento e controle dos atributos de qualidade críticos em um intermediário de purificação de proteína e para monitorar e controlar os níveis de excipientes no fluido de cultura de células colhido e/ou intermediário de purificação de proteína, e, intermediário de purificação de proteína |
| CA3113037A1 (en) * | 2018-09-26 | 2020-04-02 | Lexicon Pharmaceuticals, Inc. | Crystalline forms of n-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oopropan-2-yl)-4-(4-(2-methyl-5-(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl)phenl)butanamide and methods of their synthesis |
| US12213970B2 (en) | 2018-10-29 | 2025-02-04 | Boehringer Ingelheim International Gmbh | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof |
| PH12021550901A1 (en) | 2018-10-29 | 2022-03-21 | Boehringer Ingelheim Int | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof |
| CN109824687B (zh) * | 2019-03-26 | 2022-03-22 | 上海凌凯医药科技有限公司 | 呋喃木糖衍生物的新合成方法 |
| JP7273997B2 (ja) * | 2019-07-05 | 2023-05-15 | 山東丹紅制薬有限公司 | Ｓｇｌｔ阻害剤の結晶形及びその使用 |
| EP3771718A1 (en) * | 2019-08-01 | 2021-02-03 | Lexicon Pharmaceuticals, Inc. | Process for preparing the crystalline form ii of sotagliflozin |
| EP3771480A1 (en) | 2019-08-01 | 2021-02-03 | Lexicon Pharmaceuticals, Inc. | Continuous process for preparing the crystalline form ii of sotagliflozin |
| WO2022144465A1 (en) | 2021-01-04 | 2022-07-07 | Charité-Universitätsmedizin Berlin | Sotagliflozin for improving left atrial function |
| WO2022155303A1 (en) | 2021-01-14 | 2022-07-21 | Lexicon Pharmaceuticals, Inc. | Sotagliflozin for treating or preventing cardiovascular diseases |
| CN113880701A (zh) * | 2021-10-10 | 2022-01-04 | 浙江司太立制药股份有限公司 | 一种抗糖尿病药物中间体及其制备方法 |
| US20250108032A1 (en) | 2023-09-28 | 2025-04-03 | Lexicon Pharmaceuticals, Inc. | Methods of treating type 1 diabetes and kidney disease |
| US20250114323A1 (en) | 2023-10-06 | 2025-04-10 | Lexicon Pharmaceuticals, Inc. | Methods of reducing the risk of cardiovascular events in patients with left ventricular hypertrophy |
| PL446852A1 (pl) * | 2023-11-27 | 2025-06-02 | Politechnika Rzeszowska im. Ignacego Łukasiewicza | Układ doprowadzający wodę do pralki |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3870699A (en) * | 1973-03-06 | 1975-03-11 | Upjohn Co | Lincomycin analogs |
| MXPA02006660A (es) * | 2000-01-07 | 2002-12-13 | Transform Pharmaceuticals Inc | Formacion, identificacion y analisis de diversas formas solidas de alto rendimiento. |
| WO2006018150A1 (de) | 2004-08-11 | 2006-02-23 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| EP1856082B1 (en) | 2005-02-23 | 2009-10-14 | Boehringer Ingelheim International GmbH | Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors |
| CN1820858A (zh) * | 2006-03-10 | 2006-08-23 | 广西中医学院制药厂 | 多相物料喷雾方法及装置 |
| TWI499414B (zh) * | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法 |
| WO2008109591A1 (en) * | 2007-03-08 | 2008-09-12 | Lexicon Pharmaceuticals, Inc. | Phlorizin analogs as inhibitors of sodium glucose co-transporter 2 |
| JP5653213B2 (ja) * | 2007-07-26 | 2015-01-14 | レクシコン ファーマシューティカルズ インコーポレイテッド | ナトリウム・グルコース共輸送体２阻害剤の調製に有用な方法及び化合物 |
| TWI472521B (zh) | 2008-07-17 | 2015-02-11 | Lexicon Pharmaceuticals Inc | （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）－２－（４－氯－３－（４－乙氧苄基）苯基）－６－（甲硫）四氫－２ｈ－哌喃－３，４，５－三醇的固體形態與其使用方法 |
-
2009
- 2009-07-01 TW TW98122274A patent/TWI472521B/zh active
- 2009-07-15 PE PE2009000944A patent/PE20100260A1/es not_active Application Discontinuation
- 2009-07-15 SG SG2012077681A patent/SG185317A1/en unknown
- 2009-07-15 KR KR1020177001061A patent/KR20170010069A/ko not_active Ceased
- 2009-07-15 PL PL11155100T patent/PL2332947T3/pl unknown
- 2009-07-15 CN CN201710477527.7A patent/CN107629097A/zh not_active Withdrawn
- 2009-07-15 NO NO11155100A patent/NO2332947T3/no unknown
- 2009-07-15 UA UAA201101832A patent/UA106048C2/uk unknown
- 2009-07-15 NZ NZ590184A patent/NZ590184A/xx unknown
- 2009-07-15 AU AU2009270973A patent/AU2009270973B2/en active Active
- 2009-07-15 CN CN2009801279245A patent/CN102112483A/zh active Pending
- 2009-07-15 EP EP11155100.8A patent/EP2332947B1/en active Active
- 2009-07-15 DK DK11155100.8T patent/DK2332947T3/da active
- 2009-07-15 PT PT111551008T patent/PT2332947T/pt unknown
- 2009-07-15 HU HUE11155100A patent/HUE035400T2/en unknown
- 2009-07-15 US US12/503,225 patent/US8217156B2/en active Active
- 2009-07-15 ES ES11155100.8T patent/ES2656357T3/es active Active
- 2009-07-15 AR ARP090102685A patent/AR072807A1/es unknown
- 2009-07-15 RU RU2011105797/04A patent/RU2505543C2/ru active
- 2009-07-15 CA CA2730931A patent/CA2730931A1/en not_active Abandoned
- 2009-07-15 JP JP2011518868A patent/JP2011528366A/ja active Pending
- 2009-07-15 MX MX2011000503A patent/MX2011000503A/es active IP Right Grant
- 2009-07-15 WO PCT/US2009/050636 patent/WO2010009197A1/en not_active Ceased
- 2009-07-15 KR KR1020117001024A patent/KR101707246B1/ko active Active
- 2009-07-15 CL CL2009001595A patent/CL2009001595A1/es unknown
- 2009-07-15 BR BRPI0916191A patent/BRPI0916191A2/pt not_active Application Discontinuation
- 2009-07-16 UY UY0001031992A patent/UY31992A/es not_active Application Discontinuation
-
2010
- 2010-12-26 IL IL210269A patent/IL210269A/en active IP Right Grant
-
2011
- 2011-01-06 ZA ZA2011/00175A patent/ZA201100175B/en unknown
- 2011-02-09 CO CO11014849A patent/CO6351797A2/es not_active Application Discontinuation
-
2012
- 2012-06-22 US US13/530,645 patent/US9067962B2/en active Active
-
2015
- 2015-09-30 JP JP2015193990A patent/JP6283337B2/ja active Active
-
2018
- 2018-03-02 HK HK18103068.1A patent/HK1243713A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR072807A1 (es) | Formas solidas del compuestos (2r,3r,4r,5s,6r)-2-(4-cloro-3-etoxibencil)fenil)6-(metiltio)tetahidro-2h-piran-3,4,5-triol y metodos para su uso como inhibidor del cotransportador 2 de sodio-glucosa (sglt2) | |
| CL2011000849A1 (es) | Proceso para la preparacion de compuestos derivados de 2-(benceno/heteroaril)-6-(hidroximetil)-piran-3,4,5-triol utiles como inhibidores de sglt. | |
| AR086320A1 (es) | Cocristales de acido citrico y l-prolina de (2s,3r,4r,5s,6r)-2-(3-((5-(4-fluorofenil)tiofen-2-il)metil)-4-metilfenil)-6-(hidroximetil)tetrahidro-2h-piran-3,4,5-triol | |
| BRPI0917196B8 (pt) | forma cristalina de um composto sendo complexo de (2s,3r,4r,5s,6r)- 2- (4- cloro- 3- (4- (2- ciclopropoxietóxi) benzil)fenil)- 6- (hidroximetil) tetraidro- 2h- piran- 3,4,5- triol, bis(l-prolina) | |
| AR096582A1 (es) | Procesos de fabricación y formas cristalinas de un inhibidor de mdm2 | |
| PT2661256T (pt) | Composições compreendendo (2s,3r,4r,5s,6r)-2-(4-cloro-3-(4-etoxibenzil)fenil)-6-(metiltio)tetra-hidro-2h-pirano-3,4,5-triol | |
| HUE035947T2 (hu) | A (2S,3R,4R,5S,6R)-2-(4-klór-3-benzilfenil)-6-(hidroximetil)tetrahidro-2H-pirán-3,4,5-triol származékainak felhasználása a diabétesz kezelésében | |
| CL2011001757A1 (es) | Uso de una composicion farmaceutica que comprende un inhibidor de sglt2 (1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofuran-3-iloxi)-bencil]-benceno, para mejorar el control glucemico. | |
| CL2010000320A1 (es) | Un compuesto 8-(1,3-dihidro-isoindol-2-ilmetil)-2,9-dihidro-1,2,7,9-tetraaza-fenalen-3-ona, como inhibidor de parp; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| CO6620055A2 (es) | Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos | |
| AR107510A2 (es) | FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(b-D-GLUCOPIRANOSIL)-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL]BENCENO Y PROCESO PARA LA PREPARACIÓN | |
| BR112012016129A2 (pt) | composto, composição, e, métodos para inibir a atividade de c-met, e para tratar câncer | |
| CO6491116A2 (es) | Derivados de 5-fluoropirimidinona | |
| CL2012000583A1 (es) | Compuestos derivados de quinazolinas sustituidas, inhibidores de los canales ionicos de potasio; composicion farmaceutica que los comprende; uso del compuesto para tratar o prevenir arritmias, controlar la frecuencia cardiaca, entre otras. | |
| EP1995260A4 (en) | THROUGH ENERGY RAYS HARDENING COMPOSITION | |
| NI200800294A (es) | Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmacéuticas que la contienen. | |
| CO6630154A2 (es) | Ciertas amino-piridazinas, composiciones de las mismas y métodos de uso de los mimos | |
| DOP2011000058A (es) | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol utiles para usar como inhibidores del transportador de sodio-glucosa | |
| ECSP12011799A (es) | Compuestos de espiropiperidina y uso farmacéutico de los mismos | |
| CL2007001711A1 (es) | Compuestos derivados de pirazolopiridina sustituida;composicion farmaceutica que los comprende;metodo de preparacion de los compuestos ,compuestos intermediarios;y su uso en el tratamiento de enfermedades,tales como tumores,artritis reumatoide,enfermedades del crecimiento vascular desregulado, entre otras. | |
| CL2008000883A1 (es) | Metodo de deteccion de compuestos capaces de antagonizar la senalizacion de il-17f/il-17a; compuesto identificado por dicho metodo; uso de una cantidad de un antagonista de senalizacion de il-17f/il-17a, composicion farmaceutica que comprende dicho a | |
| NZ630408A (en) | Process for preparation of benzylbenzene sodium-dependent glucose cotransporter 2 (sglt2) inhibitors | |
| RS54488B1 (en) | NALOXOL-POLYETHYLENE GLYCOL CRYSTAL CONJUGATE | |
| CR20140007A (es) | N-(6-((2r, 3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio) pirimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina | |
| AR081732A1 (es) | Composicion de control de fitoenfermedades y metodo para controlar fitoenfermedades |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |